Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CDX-301 + PGV 001 + Poly ICLC |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CDX-301 | Mobista|CDX 301|CDX301 | Mobista (CDX-301) is a recombinant Flt3 ligand that binds to and activates the Flt3 receptor, potentially leading to proliferation of immune precursor cells (PMID: 25915810). | ||
PGV 001 | PGV001|PGV-001 | PGV 001 is a personalized cancer vaccine comprised of synthetic peptides analogous to the neoantigens present on the patient's tumor, resulting in an immune response (PMID: 29403468). | ||
Poly ICLC | Hiltonol | Hiltonol (poly ICLC) is a synthetic double stranded RNA complex, which induces interferon production and stimulates anti-tumor immune response (PMID: 22126373). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05010200 | Phase I | CDX-301 + PGV 001 + Poly ICLC PGV 001 + Poly ICLC | The Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in the Adjuvant Setting. (PGV-Prostate) | Active, not recruiting | USA | 0 |